Guardant Health (GH) Expected to Post Earnings on Thursday

Key Points

• Guardant Health is expected to report Q3 2026 results on November 5 after the market closes, with analysts projecting a loss of $0.75 per share and revenue of $350.72 million.
• The company’s prior quarter beat expectations, reporting a $0.42-per-share loss versus the expected $0.76 loss, while revenue rose 44.3% year over year to $334.98 million.
• Investor sentiment is broadly positive, with a consensus “Moderate Buy” rating and a $191 price target, although insiders sold about $30.1 million of stock over the past 90 days.

Guardant Health (NASDAQ:GH - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.75) per share and revenue of $350.72 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.34. The firm had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. Guardant Health's revenue was up 44.3% on a year-over-year basis. During the same period last year, the business earned ($0.44) EPS. On average, analysts expect Guardant Health to post ($3.08) EPS for the current fiscal year and ($2.01) EPS for the next fiscal year.

Guardant Health Trading Up 2.5%

Guardant Health stock opened at $182.59 on Thursday. The firm has a market cap of $24.50 billion, a price-to-earnings ratio of -52.32 and a beta of 1.58. Guardant Health has a 12 month low of $68.02 and a 12 month high of $191.05. The stock has a fifty day simple moving average of $169.05 and a two-hundred day simple moving average of $129.95.

Insider Activity at Guardant Health

In other Guardant Health news, Director Alex Azar, II sold 826 shares of the business's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total value of $144,550.00. Following the completion of the sale, the director directly owned 825 shares of the company's stock, valued at $144,375. The trade was a 50.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Terilyn Monroe sold 46,300 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total value of $7,645,056.00. Following the completion of the transaction, the insider directly owned 22,979 shares in the company, valued at approximately $3,794,292.48. This trade represents a 66.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 178,940 shares of company stock worth $30,070,911 over the last ninety days. 5.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on GH shares. Barclays lifted their price target on shares of Guardant Health from $200.00 to $220.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 7th. Morgan Stanley raised their price target on Guardant Health from $185.00 to $200.00 and gave the company an "overweight" rating in a report on Monday, October 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Guardant Health in a report on Thursday, October 15th. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $185.00 to $195.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Finally, The Goldman Sachs Group reissued a "buy" rating and set a $210.00 price target on shares of Guardant Health in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $191.00.

About Guardant Health

Guardant Health, Inc NASDAQ: GH is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company's products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient's response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.